MS and Demyelinating Disorders

At the 2023 ACTRIMS, the post-doctoral associate in the department of clinical neurosciences at the University of Calgary, spoke on the impact of researching T-Bet+ memory B cells for new therapies in multiple sclerosis. [WATCH TIME: 5 minutes]

At the 2023 ACTRIMS Forum, the post-doctoral associate in the department of clinical neurosciences at the University of Calgary talked about the main findings he observed with B cell therapies in patients with MS. [WATCH TIME: 4 minutes]

Here's some of what is coming soon to NeurologyLive® this week.

Omar Al-Louzi, MD, director of the Visual Outcomes Laboratory at Cedars Sinai, provided his clinical perspective on role of imaging and viral infections in patients with MS at the 2023 ACTRIMS forum.

Despite higher baseline scores, Expanded Disability Status Scale scores remained stable over time in Black patients treated with ocrelizumab for multiple sclerosis.

Neurology News Network for the week ending March 11, 2023. [WATCH TIME: 3 minutes]

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending March 10, 2023.

The associate professor at Harvard Medical School talked about the currently approved therapies and the state of care for patients with NMOSD from a clinician perspective. [WATCH TIME: 5 minutes]

Expression of CD16 and activation markers in natural killer and natural killer-T cells may be responsible for the escalating autoimmune activity in NMOSD.

A group of experts in the care of patients with multiple sclerosis—Marisa McGinley, DO; Farrah Mateen, MD, PhD; Laura Piccio, MD, PhD; Robert Zivadinov, MD, PhD; and Bruce Cree, MD, PhD, MAS, FAAN—shared their perspectives on hot topics of treatment and management from the 2023 ACTRIMS Forum.

The clinical research director of the UCSF Multiple Sclerosis Center spoke about the barriers in accessing proven therapies for NMOSD at the 2023 ACTRIMS Forum. [WATCH TIME: 3 minutes]

The associate director of the Multiple Sclerosis & Neuromyelitis Optica Unit at Massachusetts General Hospital discussed the ways employers and clinicians can alleviate work hardships experienced by patients with NMOSD. [WATCH TIME: 3 minutes]

The director of IT and Neuroinformatics Development at the Buffalo Neuroimaging Analysis Center provided perspective on the sudden explosion of artificial intelligence, and how it can be applied to MS care.

Rajiv Jain, PhD, post-doctoral associate, department of clinical neurosciences, University of Calgary, talked about his presentation on T-bet+ memory B-cells in multiple sclerosis at the 2023 ACTRIMS Forum.

The clinical assistant professor of neurology at Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, New York, talked about her presentation on Evusheld at the 2023 ACTRIMS Forum. [WATCH TIME: 5 minutes]

The effect of cognitive rehabilitation on personalized cognitive goals was specifically found 6 months after treatment completion, whereas the benefits on patient-reported cognitive complains did not persist.

Taylor Gonyou, DO, a multiple sclerosis fellow at Michigan Institute for Neurologic Disorders, detailed a proteomic biomarker panel that gauges multiple sclerosis disease activity, with potential to impact clinical decision-making.

The director of the Buffalo Neuroimaging Analysis Center provide perspective on innovative ways to monitor progression in multiple sclerosis, and the importance of high-level care facilities. [WATCH TIME: 5 minutes]

Here's some of what is coming soon to NeurologyLive® this week.

Svetlana P. Eckert, MD, clinical assistant professor of neurology at University at Buffalo, talked about Evusheld as a preventive approach to COVID-19 infections in multiple sclerosis at the 2023 ACTRIMS Forum.

At the 2023 ACTRIMS Forum, the clinical research director of the UCSF Multiple Sclerosis Center talked about the implications for patients on B-cell depleting therapies infected with COVID-19. [WATCH TIME: 4 minutes]

Nine of the 10 participants with NMOSD included in the case series have remained relapse-free after switching to satrlizumab from previous therapy.

Neurology News Network for the week ending March 4, 2023. [WATCH TIME: 3 minutes]

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending March 3, 2023.

Between the 2 therapies, ozanimod was associated with significantly lower risks of safety outcomes, including adverse events leading to discontinuation, herpetic infections, bradycardia, and abnormal liver enzymes.